

**Committee on Public Health
Bill Summary**

Bill No. H2372

Title: *An Act relative to collaborative drug therapy management optimization*

Sponsor: Representative Christine P. Barber

Committee: Public Health

Hearing Date: June 11, 2025

Similar Matters: None

Prior History: Refile of H2134 of 2023-2024; Referred to Committee on Public Health; Accompanied S1385.

Reporting Deadline: August 10, 2025

Current Law:

- **M.G.L. Chapter 112 §24 B 1/2** permits collaborative drug therapy management in ambulatory care clinics with on-site supervision by the attending physician and a collaborating pharmacist, subject to approval by the ambulatory care clinic's medical staff executive committee or designee, or medical director or designee. Defines collaborative drug therapy management as “the initiating, monitoring, modifying and discontinuing of a patient's drug therapy by a pharmacist in accordance with a collaborative practice agreement; provided, however, that collaborative drug therapy management may include: collecting and reviewing patient histories; obtaining and checking vital signs, including pulse, temperature, blood pressure and respiration; and, under the supervision of, or in direct consultation with, a physician, ordering and evaluating the results of laboratory tests directly related to drug therapy when performed in accordance with approved protocols applicable to the practice setting and when the evaluation shall not include a diagnostic component.
- **M.G.L. c. 111, § 51** governs the licensing of ambulatory care clinics

Summary:

This bill permits collaborative drug therapy management in ambulatory care clinics with on-site or off-site supervision by the attending physician and a collaborating pharmacist, subject to approval by the ambulatory care clinic's medical staff executive committee or designee, or medical director or designee.